• 100% patient satisfaction with SPONTAN nasal spray in post-prostatectomy erectile dysfunction
• All patients preferred SPONTAN over traditional oral ED therapies
• Large underserved market: ~8,500 radical prostatectomies annually in Australia and hundreds of thousands globally

LTR Pharma Limited (ASX:LTP) announced that a case series of four patients demonstrating the efficacy of SPONTAN® in treating erectile dysfunction following radical prostatectomy was presented at the 25th Asia-Pacific Prostate Cancer Conference (APCC) in Sydney. The case studies showed compelling outcomes, with 100% reporting satisfaction with SPONTAN therapy and all preferring SPONTAN over traditional ED treatments. Patients particularly valued the spontaneity and ease of administration that SPONTAN provides. Erectile dysfunction is one of the most common and persistent side effects for men after radical prostatectomy, with oral PDE5 treatments often failing to deliver adequate outcomes. Studies show that 50% of men discontinue oral PDE5 inhibitors, citing lack of spontaneity and poor tolerability. Each year in Australia alone, ~8,500 men undergo radical prostatectomy, and globally, the patient population numbers in the hundreds of thousands annually, representing a large, underserved treatment market where SPONTAN offers a differentiated and highly valued therapeutic option. The case series adds to LTR Pharma's growing clinical validation package and supports the progression of SPONTAN through late-stage development and regulatory pathways in Australia, the US, and other key markets.

LTR Pharma is preparing for the introduction of ROXUS, a variation of SPONTAN, in the US market under the personalised healthcare pathway, further advancing its global expansion strategy. Together, these findings and initiatives de-risk SPONTAN's clinical development and position LTR Pharma to advance toward regulatory milestones and commercialisation.